Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1
2010-02-12
Zensun signed refinancing contract with a local investment company recently. This investment will be specifically used for Chinese phase III clinical trial of rhNRG-1. So far, the survival study of phase II clinical trial has enrolled more than half of patients. We believe this investment will accelerate our phase III clinical trial and promote Zensun’s new round of refinancing.
More
Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to